AbbVie and Allergan divestitures are in, and an old AstraZeneca drug comes home
When AbbVie announced their $63-billion Allergan acquisition last year, executives acknowledged the two companies would have to divest some drugs to satisfy regulators. The two main assets in discussion have now been sold off – and one of them is coming home.
AstraZeneca will acquire brazikumab, Allergan’s late-stage IL-23 candidate for Crohn’s disease and ulcerative colitis. The drug was originally developed by AstraZeneca’s defunct subsidiary MedImmune, in collaboration with Amgen. Allergan licensed it for $250 million upfront and $1.27 billion in milestones.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.